PARP inhibitors, used to treat patients with cancer of the breast, ovaries, prostate and pancreas, work by inducing persistent DNA gaps in tumor cells with BRCA1 and BRCA2 mutations. The discovery offers the potential to monitor tumors for the development of resistance to PARP inhibitor therapy, and to identify drug combinations that could prevent drug resistance and improve the efficacy of cancer therapies.